Clinical Trial

Comparing Efficacy and Safety of Telitacicept and Belimumab in Lupus Nephritis: A Retrospective Multicenter Cohort Study.

Completed
View on ClinicalTrials.gov →
Summary
The objective of this observational study is to compare the efficacy and safety of telitacicept and belimumab in the treatment of lupus nephritis in patients aged 18-65 years with lupus nephritis. The main question it aims to answer is: What are the response rates of the two drugs for the main renal therapy in the lupus nephritis population? Which drug has better efficacy and safety? This study is a retrospective study. The participants will not receive any treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-13.
Status change: Active, Not Recruiting → Completed 2026-01-29
Trial Details
NCT Number NCT07031674
Lead Sponsor Yipeng Liu
Collaborators: Renmin Hospital of Wuhan University, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Beijing Friendship Hospital
Conditions Lupus Nephritis, Belimumab
Enrollment 56 participants
Start Date 2025-10-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-02